Celiker A, Ozer S, Ozme S, Ozkutlu S, Kahramanyol O
Hacettepe University Institute of Child Health, Ankara.
Turk J Pediatr. 1990 Apr-Jun;32(2):85-92.
The aim of this prospective study was to evaluate the efficacy of propafenone in suppressing various arrhythmias in a group of children who were patients in the Pediatric Cardiology Unit of Hacettepe University Children's Hospital. Seven of the 13 children (53.8%) with ventricular ectopics, all three children with paroxysmal re-entry atrioventricular tachycardia, and two of the three children with paroxysmal atrial tachycardia were treated successfully with propafenone. The drug did not cause any side effects or arrhythmogenesis. The median dosage of propafenone at discharge was 300 mg/m2/day (range 250-400 mg/m2/day) every eight hours. Our findings confirm the efficacy and safety of propafenone for the treatment of childhood arrhythmias.
这项前瞻性研究的目的是评估普罗帕酮对一组在哈杰泰佩大学儿童医院儿科心脏病科就诊的儿童各种心律失常的抑制效果。13名患有室性早搏的儿童中有7名(53.8%)、3名阵发性折返性房室心动过速患儿全部、3名阵发性房性心动过速患儿中的2名使用普罗帕酮治疗成功。该药物未引起任何副作用或心律失常。出院时普罗帕酮的中位剂量为每8小时300mg/m²/天(范围250 - 400mg/m²/天)。我们的研究结果证实了普罗帕酮治疗儿童心律失常的有效性和安全性。